Amarin Corp. PLC’s 28-month bid to block imports of some omega-3 ingredients in litigation that questioned the Food and Drug Administration’s oversight of the entire dietary supplement industry ended with a single line posted by the US Supreme Court.
The High Court on 9 December included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider civil litigations and criminal convictions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?